LiteDD’s LIT0922 Approved for Phase I Trial in Marker-Expressing Advanced Solid Tumors
The Center for Drug Evaluation (CDE) of China has approved LiteDD’s Category 1 product LIT0922...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4602 Clinical Study in Advanced Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical...
Jiangsu Cowin Biotech Obtains NMPA License for Gene Methylation Detection Kit
China-based Jiangsu Cowin Biotech Co., Ltd. (SHA: 688426) announced receiving a Category III medical device...
InventisBio Announces Positive Phase II Results for D-2570 in Psoriasis Treatment
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) announced positive results from the Phase II study...
Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved by EU for Hepatocellular Carcinoma
US giant Bristol-Myers Squibb (BMS, NYSE: BMY) announced receiving marketing approval from the European Commission...
Roche Launches Genentech Innovation Center in Boston to Accelerate Drug Development
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the launch of the Roche Genentech Innovation...
Sansure Biotech Plans RMB130 Million Investment in Shenzhen GeneMind for Gene Sequencing Expansion
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced plans to invest RMB130 million...
AbbVie’s Skyrizi Approved by China’s NMPA for Moderate to Severe Crohn’s Disease
US giant AbbVie (NYSE: ABBV) announced receiving marketing approval from China’s National Medical Products Administration...
Sun Pharma to Acquire Checkpoint Therapeutics for USD355 Million, Focusing on Cancer Immunotherapy
India-based Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced plans to acquire all outstanding shares of...
Pfizer’s Elrexfio Receives Conditional NMPA Approval for Relapsed Multiple Myeloma
US giant Pfizer (NYSE: PFE) announced receiving conditional approval from China’s National Medical Products Administration...
MicroPort Scientific Corp. Reports 10% Revenue Growth and 58% Net Loss Decrease in 2024
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) released its 2024 full-year performance estimation....
SonoScape Medical Corp. Wins First AI-Powered Prenatal Ultrasound Approval in China
Shenzhen-based SonoScape Medical Corp. announced receiving marketing approval in China for its S-Fetus prenatal ultrasound...
TYK Medicines Inc.’s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis
Zhejiang-based TYK Medicines Inc. (HKG: 2410) announced positive results from a pivotal Phase II study...
Anlong Biopharmaceutical and Sun-Novo Partner to Advance siRNA Technology in Cardiovascular Treatments
On March 10, 2025, Anlong Biopharmaceutical and Sun-Novo Pharmaceutical announced a strategic partnership to advance...
AIM Vaccine Co. Ltd Receives NMPA Approval for Human Diploid Rabies Vaccine Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...
NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter
NewCo is a new transaction model developed by Chinese innovative drug companies in response to...
Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development
Hangzhou Chance Pharmaceuticals recently announced the completion of a new funding round, led by Zhejiang’s...
Sino Biopharmaceutical Licenses Nanjing Delova’s QP001 for Mainland China Rights
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced acquiring exclusive rights to Nanjing Delova Biotech Co.,Ltd’s...
Fosun Pharmaceutical’s Foritinib Accepted for Review by China’s NMPA for NSCLC Treatment
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that the National...
Everest Medicines Begins Clinical Trial for Personalized mRNA Cancer Vaccine EVM16
China-based Everest Medicines (HKG: 1952) has announced the first patient dosing of an investigator-initiated clinical...